IOncology

The development of modern oncology has provided a variety of groundbreaking treatment options for lung cancer, making it one of the most rapidly evolving solid tumors. To help clinical physicians gain an in-depth and comprehensive understanding of the significant advancements in this field, "Oncology Frontier" has joined forces with Dr. Hua Zhong and Dr. Baohui Han, Director of the Department of Respiratory and Critical Care Medicine at Shanghai Jiao Tong University School of Medicine Affiliated Chest Hospital,  to create a clinical progress series called "Zhong's Insights, Hui's Wisdom." By interpreting high-quality clinical studies in the field of lung cancer, this series aims to promote the improvement of clinical diagnostic and treatment practices. In this 23rd issue of the “Zhong's Insights, Hui's Wisdom” series, Dr. Hua Zhong and Dr. Baohui Han provide their expert analysis on the relationship between PD-L1 expression levels and the efficacy of first-line crizotinib treatment in ROS-1 fusion-positive non-small cell lung cancer (NSCLC) patients. The study was published in Lung Cancer by the Department of Respiratory and Critical Care Medicine at Shanghai Jiao Tong University School of Medicine Affiliated Chest Hospital, with Dr. Runbo Zhong as the corresponding author.

The 2024 World Conference on Lung Cancer (WCLC) will be held in San Diego, USA, from September 7-10. Dr. Matthew Smeltzer, Associate Professor , Division of Epidemiology, Biostatistics, and Environmental Health at the University of Memphis, Tennessee, will present the analysis of the "2024 International Association for the Study of Lung Cancer (IASLC) Global Survey on Biomarker Testing" in an oral session titled "OA03 Predicting the Future: New Pathology Assessments and Imaging Biomarkers."

The 2024 World Conference on Lung Cancer (WCLC), hosted by the International Association for the Study of Lung Cancer (IASLC), is currently underway in San Diego, USA. Oncology Frontier has invited leading Chinese lung cancer experts to analyze the key research data from this conference. This article highlights Dr. Nan Bi from the Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College, as she shares her thoughts on the LAURA study results (Abstract No. OA12.03).

At the 2024 World Conference on Lung Cancer (WCLC), the International Association for the Study of Lung Cancer (IASLC), the Chinese Society of Clinical Oncology (CSCO), and the Chinese Alliance Against Lung Cancer (CAALC) came together once again to host a joint session. Held on Saturday, September 7, from 8:00 AM to 12:00 PM, the session focused on the development and future prospects of evidence-based medicine in lung cancer prevention worldwide. The session was chaired by IASLC President-Elect, Dr. Caizun Zhou from Shanghai East Hospital, alongside Dr. Yilong Wu from Guangdong Provincial People's Hospital, IASLC CEO Dr. Karen Kelly, and Dr. Chunxue Bai from Fudan University’s Zhongshan Hospital.

The IASLC 2024 World Conference on Lung Cancer (WCLC 2024) was held in San Diego, CA USA on September 7th. The mOS data from the INTELLECT study was disclosed at the conference on September 8th. Oncology Frontier has invited the lead principal investigator of the INTELLECT study, Dr. Yuankai Shi from the Cancer Hospital Chinese Academy of Medical Sciences, to share the latest findings from this groundbreaking research reported at the WCLC. This study highlights the promising outcomes of Iruplinakib treatment for advanced NSCLC patients resistant to crizotinib.

The 2024 World Conference on Lung Cancer (WCLC) marks the 50th anniversary of the International Association for the Study of Lung Cancer (IASLC). This milestone celebration will feature unique activities commemorating IASLC’s rich history, under the theme "Across the Decades." The event will be held on September 8 in San Diego’s famous Gaslamp Quarter, where attendees can enjoy local cuisine, dance, and commemorative attire throughout the evening.

Vebreltinib, a highly potent and selective c-MET (mesenchymal-epithelial transition) inhibitor, offers a promising treatment option for patients with MET exon 14 skipping mutation (METex14) in non-small cell lung cancer (NSCLC). Can it provide a safe and effective therapy for these patients?

A large population-based cohort study led by Dr. Mollie E. Barnard from the Huntsman Cancer Institute at the University of Utah has found that women with endometriosis have an overall higher risk of ovarian cancer, with the risk being significantly elevated in those with severe types of endometriosis. This study, published in the journal of the American Medical Association [1], suggests that these women may benefit from counseling on ovarian cancer risk and prevention, as well as potential ovarian cancer screening.

With an international perspective and a focus on leading-edge advancements, the Overseas Experts China Tour project welcomed a prominent figure in the field of lung cancer from August 5th to 10th, 2024—Dr. Jürgen Wolf, Director of the Centre for Integrated Oncology (CIO) at University Hospital of Cologne, Professor of Interdisciplinary Translational Oncology at the University of Cologne, and Head of the CIO Lung Cancer Program. During his five-day academic exchange tour in China, Professor Wolf visited Chengdu, Hangzhou, Changsha, and Qingdao, attracting lung cancer experts from across the country for discussions and exchanges. Throughout these academic activities, Professor Wolf not only shared the experiences of lung cancer diagnosis and treatment in Germany but also engaged in vigorous academic discussions with Chinese experts on the latest advancements and contentious topics in lung cancer treatment, sparking many brilliant ideas.